Several other equities analysts have also recently issued reports on the company. BidaskClub cut Athenex from a hold rating to a sell rating in a research note on Thursday, January 4th. JPMorgan Chase & Co. began coverage on Athenex in a research note on Wednesday, October 18th. They issued a neutral rating and a $22.20 price objective for the company. Finally, Laidlaw began coverage on Athenex in a research note on Tuesday, September 19th. They issued a buy rating and a $36.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $27.64.
Shares of Athenex (NASDAQ ATNX) traded up $0.12 on Wednesday, hitting $17.33. The stock had a trading volume of 221,469 shares, compared to its average volume of 141,121. Athenex has a fifty-two week low of $11.21 and a fifty-two week high of $20.79.
Several hedge funds and other institutional investors have recently modified their holdings of ATNX. Jaffetilchin Investment Partners LLC acquired a new stake in shares of Athenex during the 4th quarter worth about $1,711,000. Laurion Capital Management LP acquired a new stake in shares of Athenex during the 2nd quarter worth about $1,600,000. Gilder Gagnon Howe & Co. LLC acquired a new stake in shares of Athenex during the 3rd quarter worth about $1,559,000. OxFORD Asset Management LLP acquired a new stake in shares of Athenex during the 2nd quarter worth about $956,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Athenex during the 2nd quarter worth about $800,000. 2.93% of the stock is currently owned by institutional investors and hedge funds.
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.